TheEdgeResearch
Home / Stocks / PTGX

Protagonist Therapeutics, Inc. (PTGX)

NASDAQ Healthcare Biotechnology
$121.40 ▼ -2.11%
Market Cap
$7.92B
Sector
Healthcare
Industry
Biotechnology
Beta
1.79
52-Wk Range
77-160.81
CEO
Dinesh V. Patel
Country
US
Currency
USD

Protagonist Therapeutics, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Newark, CA, US. The stock last traded at $121.40, down 2.11% on the session, giving a market capitalisation of $7.92B. On trailing twelve-month figures it carries a trailing P/E of 23.54, a net margin of 62.0%. Its beta of 1.79 implies it has historically moved more than the broad market.

Valuation & profitability (TTM)
P/E
23.54
Price / Sales
14.36
Price / Book
7.43
EV / EBITDA
21.15
Gross margin
99.7%
Operating margin
58.6%
Net margin
62.0%
Return on equity
—
Debt / equity
0.01
Current ratio
19.85
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
NASDAQ Global Market
Employees
149
IPO date
2016-08-11
Headquarters
Newark, CA, US
About Protagonist Therapeutics, Inc.

Protagonist Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering and advancing peptide-based therapies. Their research primarily focuses on treatments for hematological and blood conditions, as well as inflammatory and immune-mediated disorders. The company's pipeline features rusfertide (PTG-300), an injectable hepcidin mimetic currently undergoing Phase II clinical trials for the management of polycythemia vera, hereditary hemochromatosis, and other blood-related ailments. Also in Phase II development is PN-943, an oral peptide engineered as a specific antagonist of alpha-4-beta-7 integrin, intended for addressing inflammatory bowel disease (IBD). Furthermore, they are progressing PN-235, an orally administered antagonist specifically targeting the interleukin-23 receptor, designed for both IBD and various non-IBD therapeutic applications. Protagonist Therapeutics maintains a licensing and collaborative agreement with Janssen Biotech, Inc. Founded in 2006, the company's headquarters are located in Newark, California.

Comparable companies

Protagonist Therapeutics, Inc. is most often compared with the following Healthcare names:

ACRSANABIMUXIMVTIRONODTXSYRE
More research on PTGX
PTGX technical analysis PTGX TheEdge Score Compare against peers
Open full interactive analysis & DCF →